Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1999-10-19
2001-07-03
Russel, Jeffrey E. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C530S350000
Reexamination Certificate
active
06255283
ABSTRACT:
The present invention relates to the use of proteins extractable from animal organs for the preparation of medicaments for the treatment of pathological conditions characterized by hyperproduction of Tumor Necrosis Factor (TNF).
TNF, also known as cachectin, is a proinflammatory cytokine playing an important role in starting, together with IL-1, the cascade of other cytokines and factors which trigger the immune response in infections and in cancer. This response is paramount for a complete resolution of infections and metastatic processes, but it can occur in an uncontrolled way, thus causing damage to the host. TNF hyperproduction is considered to be involved in a number of pathological conditions, such as septic shock, tumor cachexia, autoimmune diseases (rheumatoid arthritis, multiple sclerosis), meningococcal septicemia, Crohn's disease, etc.
WO 92/10197 disclosed protein fractions extractable with perchloric acid from organs of mammals, and their use as anticancer agents. Within these fractions, three main components could be identified, having molecular weights of 50, 14 and 10 KDa on gel electrophoresis. Hereinafter, the purified extract containing these three components will be referred to as UK 101. The sequence of the 14 KDa component, which is the main, if not the only protein, responsible for the described activities, is reported in WO 96/02567 and it has turned out to be related to that described by other authors (Levy-Favatier, Eur. Biochem. 1903, 212 (3) 665-73) who have assumed that the novel identified sequences belong to the family of the proteins known as chaperonins, to which the HSPs (Heat Shock Proteins) themselves belong.
The proteins described in WO 92/10197 and those of WO 96/02567 (hereinafter referred to as UK 114) show properties not previously observed in chaperonins or analogous proteins. Now it has been found, in particular, that said proteins are capable of significantly lowering TNF blood levels and therefore they can be used for the treatment of pathological conditions characterized by hyperproduction of TNF.
The invention relates particularly to the use of the purified protein UK 114.
Moreover the invention comprises the use of proteins showing high homology to UK 114, of at least 80%, especially of 90% or more.
REFERENCES:
patent: 5997873 (1999-12-01), Srivastava
patent: 6007821 (1999-12-01), Srivastava et al.
patent: 2 251 186 (1992-07-01), None
patent: 93/18146 (1993-09-01), None
patent: 96 02567 (1996-02-01), None
patent: 96 10039 (1996-04-01), None
patent: 98 11909 (1998-03-01), None
Chemical Abstracts, vol. 119, No. 7, Aug. 16, 1993, Abstract No. 65937, XP002075248, F. Levy-Favatier et al, “Characterization, purification and cDNA cloning of a rat perchloric-acid-soluble 23 kDa protein etc.”
Bartorelli Alberto
Meroni Pier Luigi
Panerai Alberto
Birch & Stewart Kolasch & Birch, LLP
Russel Jeffrey E.
Zetesis S.p.A.
LandOfFree
Use of proteins extractable from animal organs for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of proteins extractable from animal organs for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of proteins extractable from animal organs for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2551791